REACTIVE MUSCLE HYPEREMIA IN CHRONIC PERIPHERAL OCCLUSIVE ARTERIAL-DISEASE TREATED BY HEMODILUTION AND ORAL-ADMINISTRATION OF PENTOXIFYLLINE

被引：0
作者：
MAURIN, N [1 ]
ANGELKORT, B [1 ]
PIRNAY, D [1 ]
机构：
[1] UNIV AACHEN,DEPT INTERNAL MED,AACHEN,FED REP GER
来源：
INTERNATIONAL JOURNAL OF MICROCIRCULATION-CLINICAL AND EXPERIMENTAL | 1982年 / 1卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：293 / 294
页数：2
相关论文
共 38 条
[31]   Optimal hematocrit in patients with peripheral occlusive arterial disease (POAD): Exercise induced muscle tissue pO2 after isovolemic hemodilution [J].
Hoffkes, HG ;
Ehrly, AM ;
Franke, A ;
Landgraf, H .
CLINICAL HEMORHEOLOGY, 1996, 16 (03) :321-327
[32]   FUNCTIONAL RESULTS AFTER ORAL TREATMENT WITH DUSODRIL IN PERIPHERAL CHRONIC ARTERIAL OCCLUSIVE DISEASE - COMPARISON OF ANGIOGRAM, PLETHYSMOGRAM AND DOPPLER [J].
WEIDINGER, P .
MEDIZINISCHE WELT, 1983, 34 (17) :531-534
[33]   Effects of ischaemic stress on leukocyte activation processes in patients with chronic peripheral occlusive arterial disease: Role of L-propionyl carnitine administration [J].
Signorelli, SS ;
Malaponte, G ;
Di Pino, L ;
Digrandi, D ;
Pennisi, G ;
Mazzarino, MC .
PHARMACOLOGICAL RESEARCH, 2001, 44 (04) :305-309
[34]   Improvement in quality of life and adverse effects in patients with chronic arterial occlusive disease treated with alprostadil alpha-cyclodextrin through the peripheral venous route [J].
Pilar Corcoles Jimenez, M. ;
Ruiz Gomez, Teresa ;
Gomariz Garcia, Soledad ;
Herreros Saez, Lucia ;
Pita Toledo, Lourdes ;
Ruiz-Risueno Alvarez, Inmaculada ;
Segovia Gil, Maria Isabel .
ENFERMERIA CLINICA, 2005, 15 (04) :206-212
[35]   Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis [J].
F J Giles ;
M J Mauro ;
F Hong ;
C-E Ortmann ;
C McNeill ;
R C Woodman ;
A Hochhaus ;
P D le Coutre ;
G Saglio .
Leukemia, 2013, 27 :1310-1315
[36]   Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis [J].
Giles, F. J. ;
Mauro, M. J. ;
Hong, F. ;
Ortmann, C-E ;
McNeill, C. ;
Woodman, R. C. ;
Hochhaus, A. ;
le Coutre, P. D. ;
Saglio, G. .
LEUKEMIA, 2013, 27 (06) :1310-1315
[37]   Effects of chronic oral L-arginine administration on the L-arginine/NO pathway in patients with peripheral arterial occlusive disease or coronary artery disease: L-Arginine prevents renal loss of nitrite, the major NO reservoir [J].
Schneider, Jessica Y. ;
Rothmann, Sabine ;
Schroeder, Frank ;
Langen, Jennifer ;
Luecke, Thomas ;
Mariotti, Francois ;
Huneau, Jean Francois ;
Froelich, Juergen C. ;
Tsikas, Dimitrios .
AMINO ACIDS, 2015, 47 (09) :1961-1974
[38]   Effects of chronic oral l-arginine administration on the l-arginine/NO pathway in patients with peripheral arterial occlusive disease or coronary artery disease: l-Arginine prevents renal loss of nitrite, the major NO reservoir [J].
Jessica Y. Schneider ;
Sabine Rothmann ;
Frank Schröder ;
Jennifer Langen ;
Thomas Lücke ;
François Mariotti ;
Jean François Huneau ;
Jürgen C. Frölich ;
Dimitrios Tsikas .
Amino Acids, 2015, 47 :1961-1974
1234